Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

General Counsel

Chief Business Officer

Chief Financial Officer

Chief Medical Officer

Chief Operating Officer

President and CEO

Chief Commercial Officer

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-20	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-03-20	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-03-20	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-18	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-02-12	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-04	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-04	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-01-04	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-01-04	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-03	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-03	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-01-03	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-03	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	President and CEO
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-03	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-01-03	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer
2024-01-03	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-02	Premium	sold	Premium	Premium	Premium	President and CEO
2023-12-11	Premium	sold	Premium	Premium	Premium	Chief Medical Officer

GTHX - G1 Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for GTHX